Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 388

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Management of multidrug-resistant enterococcal infections

Open access
Arias, C.A., Contreras, G.A., Murray, B.E.·2010·Clinical Microbiology and Infection
DOI 10.1111/j.1469-0691.2010.03214.x
Open this paper in CoChat — free account

Abstract

Enterococci are organisms with a remarkable ability to adapt to the environment and acquire antibiotic resistance determinants. The evolution of antimicrobial resistance in these organisms poses enormous challenges for clinicians when faced with patients affected with severe infections. The increased prevalence and dissemination of multidrug-resistant Enterococcus faecium worldwide has resulted in a major decrease in therapeutic options because the majority of E. faecium isolates are now resistant to ampicillin and vancomycin, and exhibit high-level resistance to aminoglycosides, which are three of the traditionally most useful anti-enterococcal antibiotics. Newer antibiotics such as linezolid, daptomycin and tigecycline have good in vitro activity against enterococcal isolates, although their clinical use may be limited in certain clinical scenarios as a result of reduced rates of success, possible underdosing for enterococci and low serum levels, respectively, and also by the emergence of resistance. The experimental agent oritavancin may offer some hope for the treatment of vancomycin-resistant enterococci but clinical data are still lacking. Thus, optimal therapies for the treatment of multidrug-resistant enterococcal infections continue to be based on empirical observations and extrapolations from in vitro and animal data. Clinical studies evaluating new strategies, including combination therapies, to treat severe vancomycin-resistant E. faecium infections are urgently needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1469-0691.2010.03214.x

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Research works printed but not linked: 16

  1. Werner, 2008, Emergence and spread of vancomycin resistance among enterococci in Europe, Euro Surveill, 20, 13
  2. Patel, 2003, Clinical impact of vancomycin‐resistant enterococci, J Antimicrob Chemother, 51, iii13
  3. Kariyama, 1998, In‐vitro activity of the combination of ampicillin and arbekacin against high‐level gentamicin‐resistant enterococci, J Antimicrob Chemother, 42, 836, 10.1093/oxfordjournals.jac.a020872 · doi:10.1093/oxfordjournals.jac.a020872
  4. Saravolatz, 2009, Telavancin: a novel lipoglycopeptide, Clin Infect Dis, 49, 1908, 10.1086/648438 · doi:10.1086/648438
  5. Lefort, 2000, Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin‐susceptible or ‐resistantEnterococcus faecalis, Antimicrob Agents Chemother, 44, 3017, 10.1128/AAC.44.11.3017-3021.2000 · doi:10.1128/aac.44.11.3017-3021.2000
  6. Saleh‐Mghir, 1999, Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin‐resistantEnterococcus faecalis, Antimicrob Agents Chemother, 43, 115, 10.1128/AAC.43.1.115 · doi:10.1128/aac.43.1.115
  7. Tsai, 2006, Short course of linezolid treatment for vancomycin‐resistantEnterococcus faecium meningitis, Int J Clin Pract, 60, 740, 10.1111/j.1368-5031.2006.00706.x · doi:10.1111/j.1368-5031.2006.00706.x
  8. Bryson, 1996, Quinupristin‐dalfopristin, Drugs, 52, 406, 10.2165/00003495-199652030-00006 · doi:10.2165/00003495-199652030-00006
  9. Bethea, 2004, Treatment of vancomycin‐resistant enterococcus with quinupristin/dalfopristin and high‐dose ampicillin, Ann Pharmacother, 38, 989, 10.1345/aph.1D377 · doi:10.1345/aph.1d377
  10. Panesso, 2002, First characterization of a cluster of VanA‐type glycopeptide‐resistantEnterococcus faecium, Colombia, Emerg Infect Dis, 8, 961, 10.3201/eid0809.010435 · doi:10.3201/eid0809.010435
  11. Norris, 1995, Chloramphenicol for the treatment of vancomycin‐resistant enterococcal infections, Clin Infect Dis, 20, 1137, 10.1093/clinids/20.5.1137 · doi:10.1093/clinids/20.5.1137
  12. Ricaurte, 2001, Chloramphenicol treatment for vancomycin‐resistantEnterococcus faecium bacteremia, Clin Microbiol Infect, 7, 17, 10.1046/j.1469-0691.2001.00189.x · doi:10.1046/j.1469-0691.2001.00189.x
  13. Safdar, 2002, Prosthetic valve endocarditis due to vancomycin‐resistantEnterococcus faecium: treatment with chloramphenicol plus minocycline, Clin Infect Dis, 34, E61, 10.1086/340527 · doi:10.1086/340527
  14. Zinner, 2008, Selection of linezolid‐resistantEnterococcus faecium in an in vitro dynamic model: protective effect of doxycycline, J Antimicrob Chemother, 61, 629, 10.1093/jac/dkm542 · doi:10.1093/jac/dkm542
  15. Van Nieuwkoop, 2008, Chronic bacterial prostatitis and relapsingEnterococcus faecalis bacteraemia successfully treated with moxifloxacin, J Infect, 56, 155, 10.1016/j.jinf.2007.11.003 · doi:10.1016/j.jinf.2007.11.003
  16. Rambaldi, 1997, Combination of co‐trimoxazole and ciprofloxacin as therapy of a patient with infective endocarditis caused by an enterococcus highly resistant to gentamicin, J Antimicrob Chemother, 40, 737, 10.1093/jac/40.5.737 · doi:10.1093/jac/40.5.737

Cited by

See all 388

Metadata

Authors
Arias, C. A., Contreras, G. A., & Murray, B. E.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2010-06
Volume
16
Issue
6
Pages
555-562
ISSN
1198-743X (ISSN-L)
DOI
10.1111/j.1469-0691.2010.03214.x
OpenAlex
W2103599303
Cited by
388
References
66
FWCI
9.39
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of multidrug-resistant enterococcal infections. https://app.cochat.ai/papers/10.1111/j.1469-0691.2010.03214.x
The paper
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010). Management of multidrug-resistant enterococcal infections. Clinical Microbiology and Infection. https://doi.org/10.1111/j.1469-0691.2010.03214.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.